权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Quantitative MRI-PET Imaging of Pulmonary Fibrosis

肺纤维化的定量 MRI-PET 成像

基本信息

批准号：
10681360
负责人：
Iris Yuwen Zhou
金额：
$ 15.96万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-25 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10681360
关键词：
Air Algorithms Animal Model Animals Binding Biometry Biopsy Blood Vessels Breathing Cardiovascular Diseases Chest imaging Clinical Clinical Trials Clinical Trials Design Collagen Collagen Type I Data Deposition Diagnosis Disease Disease Progression Early Diagnosis Fibrosis Freezing Functional disorder Gallium Goals Grant High Resolution Computed Tomography Human Image Image Analysis Imaging Device Individual Label Lung Magnetic Resonance Magnetic Resonance Imaging Maps Measurement Measures Mentors Metabolism Methods Modeling Molecular Molecular Abnormality Monitor Morphologic artifacts Morphology Motion Oncology Outcome Output Pathogenicity Patient Care Patients Phase Photons Physics Physiology Positron-Emission Tomography Predisposition Process Prognosis Protocols documentation Protons Pulmonary Fibrosis Pulmonary function tests Radial Research Research Proposals Rotation Sampling Scheme Selection for Treatments Services Signal Transduction Stable Disease Structure of parenchyma of lung Techniques Therapeutic Effect Therapeutic Intervention Time Tissues Training Translating Variant Writing X-Ray Computed Tomography anatomic imaging attenuation blood fractionation career contrast enhanced contrast imaging density design drug development fibrotic lung first-in-human healthy volunteer human disease idiopathic pulmonary fibrosis imaging approach improved in vivo indium-bleomycin injured lung imaging lung injury molecular imaging nervous system disorder novel novel therapeutic intervention optimal treatments programs pulmonary function quantitative imaging radiological imaging respiratory segmentation algorithm simulation skills treatment response uptake

项目摘要

Project Summary/Abstract The goal of this project is to develop and implement a MR-PET lung imaging tool to accurately quantify molecular abnormalities associated with pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease with a median survival of less than 4 years from the time of diagnosis. The treatment options remain limited due to highly variable clinical course and poorly understood pathogenic mechanisms. Current strategies to diagnose and monitor IPF include lung biopsy, pulmonary function tests that measure global lung function, and anatomic imaging tools such as high-resolution computed tomography. Yet these methods are limited in their ability to detect disease early, determine disease activity, provide accurate prognosis or monitor the therapeutic response. Molecular imaging may be an alternative approach that is more sensitive to detect early fibrosis and potentially capable of distinguishing new, active fibrosis from stable disease – urgent and unmet clinical needs. Advancing the capacity of quantitative imaging tools to determine IPF disease activity would improve patient care and facilitate much-needed drug development. Our central hypothesis is that non- invasive MR-aided PET imaging of collagen accumulation will allow us to capture the extent of ongoing lung injury in IPF patients and thus service as a viable disease activity measure. Magnetic resonance (MR) imaging can provide multiple readouts of morphology, physiology, metabolism, and molecular processes, while positron emission tomography (PET) offers exquisite sensitivity to interrogate pathobiology. Advanced MR and PET techniques have had major impacts in oncology, cardiovascular diseases, and neurological disorders. However, their application to lung imaging has been historically limited because of low proton density and the fast signal decay due to susceptibility artefacts at air-tissue interfaces for MRI, while PET quantification remains challenging due to respiratory motion, photon attenuation and regional variations in tissue, air and blood fractions. Recently, we developed a gallium(Ga)-68 labeled collagen binding PET probe for fibrosis imaging. Ex vivo measurement showed a 5-fold higher uptake in bleomycin injured fibrotic lungs than controls. However, both in vivo animal and first-in-human studies showed a PET signal difference of 35-40%. This discrepancy highlights the importance of motion, attenuation and partial volume correction in PET quantification. Our preliminary simulation results show that attenuation and motion correction substantially increase the imaging contrast. Recent technical advances such as parallel imaging, ultra-short time to echo (UTE) and rotating phase encoding have enabled advanced proton MR imaging of the lung. Thus simultaneous MR-PET promises to improve PET quantification by using the spatially and temporally correlated MR information to correct for motion, partial volume and photon attenuation effects. Capitalizing on the technical advances in imaging and the sensitive collagen-targeted probe, this proposal aims to establish an MR-PET lung imaging tool to accurately quantify collagen deposition in the lung of IPF patients for precise assessment of disease activity.

项目总结/文摘